Patent ID: 9226919
Filing Date: 2016-01-05
CPC Classification: A61K,A61P

Claim Text:
1. A method for treating or managing a muscular dystrophy resulting from a premature stop codon in mRNA encoded by the dystrophin gene in a patient having a muscular dystrophy resulting from a premature stop codon in mRNA encoded by the dystrophin gene, comprising administering to the patient an effective amount of 3-[5-(2-fluoro-phenyl)-[1,2,4]oxadiazol-3-yl]-benzoic acid or a pharmaceutically acceptable salt thereof in three doses per day, wherein the first dose administered is in a range of from about 18 mg/kg to about 22 mg/kg, the second dose administered is in a range of from about 18 mg/kg to about 22 mg/kg and the third dose administered is in a range of from about 35 mg/kg to about 40 mg/kg, in a plurality of 24 hour time periods, wherein the second dose is administered about 6 hours after the first dose is administered, the third dose is administered about 6 hours after the second dose is administered, and the first dose for a next 24 hour time period is administered about 12 hours after the third dose was administered for a preceding 24 hour time period, and wherein a plasma concentration of 3-[5-(2-fluoro-phenyl)-[1,2,4]oxadiazol-3-yl]-benzoic acid or a pharmaceutically acceptable salt thereof in a range of about 2 μg/mL to about 20 μg/mL is maintained in said patient for a 24 hour time period.